Free Trial
NYSEAMERICAN:VTAK

Catheter Precision Q2 2024 Earnings Results & Report

Catheter Precision logo
$0.15 0.00 (0.00%)
As of 10/9/2026

Catheter Precision reported Q2 2024 earnings on August 14, 2024. The company reported EPS of -$1,058.30, while revenue was $90 thousand.

Earnings Announcement Details

Quarter
Q2 2024
Report Date

Catheter Precision EPS Results

Actual EPS
-$1,058.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Catheter Precision Revenue Results

Actual Revenue
$90 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Catheter Precision's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Catheter Precision Q2 2024 Earnings FAQ

Catheter Precision (NYSEAMERICAN:VTAK) reported earnings of -$1,058.30 per share for Q2 2024. The report was announced on Wednesday, August 14, 2024.

Catheter Precision reported revenue of $90 thousand for Q2 2024.

Catheter Precision's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Catheter Precision on the company's earnings history page.

Catheter Precision Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Catheter Precision Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Catheter Precision? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catheter Precision and other key companies, straight to your email.

About Catheter Precision

Catheter Precision (NYSEAMERICAN:VTAK) is a medical device company focused on developing technologies for cardiac electrophysiology, a field involving the diagnosis and treatment of heart-rhythm disorders. Its products are designed to support physicians during procedures used to evaluate and treat cardiac arrhythmias, including ventricular tachycardia and other irregular heart rhythms.

The company’s product portfolio includes the VIVO system, a noninvasive 3D cardiac mapping and navigation platform intended to help clinicians identify the origin of ventricular arrhythmias and plan catheter-ablation procedures. Catheter Precision also markets LockeT, a device designed to help secure and manage catheters during electrophysiology procedures and support post-procedure access-site management.

Catheter Precision was formerly known as Ra Medical Systems and adopted its current name as it shifted its focus toward cardiac electrophysiology technologies. The company serves hospitals, cardiac centers and electrophysiology specialists, primarily in the United States and selected international markets where its products have received applicable regulatory clearances or approvals.

View Catheter Precision Profile